Castration-resistant prostate cancer: Novel therapeutics pre- or post-taxane administration

Masaki Shiota, Akira Yokomizo, Naohiro Fujimoto, Hidetoshi Kuruma, Seiji Naito

Research output: Contribution to journalReview article

16 Citations (Scopus)

Abstract

Until 2010 docetaxel was the only agent with a proven survival benefit in the treatment of castration-resistant prostate cancer (CRPC). Recent evidence suggests that CRPC is caused by augmented androgen/androgen receptor (AR) signaling involving AR hypersensitivity, promiscuous activation of the AR, de novo production of androgens and activation of the AR by cytokines and growth factors; these findings have led to the development of novel agents targeting AR signaling. Several novel drugs targeting the AR axis, including the cytochrome P17 inhibitor abiraterone acetate and anti-androgen enzalutamide (MDV3100), have shown promising results in prolonging survival in clinical trials in a postchemotherapy setting. Because of these encouraging findings, these drugs have also been evaluated in a pre-chemotherapy setting. In addition, several novel drugs targeting non-AR signaling, including the novel taxoid compound cabazitaxel, antisense oligonucleotide OGX-011 (custirsen), sipuleucel-T immunotherapy and Alpharadin-based radiotherapy, have also been demonstrated to improve overall survival in CRPC. However, there is no consensus with regard to the sequence in which these novel drugs and taxanes should be used in the treatment of CRPC. In this review, we summarize recently developed and developing novel agents for use against CRPC. We also discuss the sequence of use of these agents and taxanes, mainly from the standpoint of factors related to drug resistance.

Original languageEnglish
Pages (from-to)444-459
Number of pages16
JournalCurrent Cancer Drug Targets
Volume13
Issue number4
DOIs
Publication statusPublished - Jun 11 2013

Fingerprint

Castration
Androgen Receptors
Prostatic Neoplasms
Taxoids
Androgens
docetaxel
Drug Delivery Systems
Therapeutics
Antisense Oligonucleotides
Cytochromes
Drug Resistance
Pharmaceutical Preparations
Immunotherapy
taxane
Intercellular Signaling Peptides and Proteins
Hypersensitivity
Radiotherapy
Clinical Trials
Cytokines
Drug Therapy

All Science Journal Classification (ASJC) codes

  • Oncology
  • Pharmacology
  • Drug Discovery
  • Cancer Research

Cite this

Castration-resistant prostate cancer : Novel therapeutics pre- or post-taxane administration. / Shiota, Masaki; Yokomizo, Akira; Fujimoto, Naohiro; Kuruma, Hidetoshi; Naito, Seiji.

In: Current Cancer Drug Targets, Vol. 13, No. 4, 11.06.2013, p. 444-459.

Research output: Contribution to journalReview article

Shiota, Masaki ; Yokomizo, Akira ; Fujimoto, Naohiro ; Kuruma, Hidetoshi ; Naito, Seiji. / Castration-resistant prostate cancer : Novel therapeutics pre- or post-taxane administration. In: Current Cancer Drug Targets. 2013 ; Vol. 13, No. 4. pp. 444-459.
@article{e1173d5d43e043b59f42d1979dd954ac,
title = "Castration-resistant prostate cancer: Novel therapeutics pre- or post-taxane administration",
abstract = "Until 2010 docetaxel was the only agent with a proven survival benefit in the treatment of castration-resistant prostate cancer (CRPC). Recent evidence suggests that CRPC is caused by augmented androgen/androgen receptor (AR) signaling involving AR hypersensitivity, promiscuous activation of the AR, de novo production of androgens and activation of the AR by cytokines and growth factors; these findings have led to the development of novel agents targeting AR signaling. Several novel drugs targeting the AR axis, including the cytochrome P17 inhibitor abiraterone acetate and anti-androgen enzalutamide (MDV3100), have shown promising results in prolonging survival in clinical trials in a postchemotherapy setting. Because of these encouraging findings, these drugs have also been evaluated in a pre-chemotherapy setting. In addition, several novel drugs targeting non-AR signaling, including the novel taxoid compound cabazitaxel, antisense oligonucleotide OGX-011 (custirsen), sipuleucel-T immunotherapy and Alpharadin-based radiotherapy, have also been demonstrated to improve overall survival in CRPC. However, there is no consensus with regard to the sequence in which these novel drugs and taxanes should be used in the treatment of CRPC. In this review, we summarize recently developed and developing novel agents for use against CRPC. We also discuss the sequence of use of these agents and taxanes, mainly from the standpoint of factors related to drug resistance.",
author = "Masaki Shiota and Akira Yokomizo and Naohiro Fujimoto and Hidetoshi Kuruma and Seiji Naito",
year = "2013",
month = "6",
day = "11",
doi = "10.2174/15680096113139990078",
language = "English",
volume = "13",
pages = "444--459",
journal = "Current Cancer Drug Targets",
issn = "1568-0096",
publisher = "Bentham Science Publishers B.V.",
number = "4",

}

TY - JOUR

T1 - Castration-resistant prostate cancer

T2 - Novel therapeutics pre- or post-taxane administration

AU - Shiota, Masaki

AU - Yokomizo, Akira

AU - Fujimoto, Naohiro

AU - Kuruma, Hidetoshi

AU - Naito, Seiji

PY - 2013/6/11

Y1 - 2013/6/11

N2 - Until 2010 docetaxel was the only agent with a proven survival benefit in the treatment of castration-resistant prostate cancer (CRPC). Recent evidence suggests that CRPC is caused by augmented androgen/androgen receptor (AR) signaling involving AR hypersensitivity, promiscuous activation of the AR, de novo production of androgens and activation of the AR by cytokines and growth factors; these findings have led to the development of novel agents targeting AR signaling. Several novel drugs targeting the AR axis, including the cytochrome P17 inhibitor abiraterone acetate and anti-androgen enzalutamide (MDV3100), have shown promising results in prolonging survival in clinical trials in a postchemotherapy setting. Because of these encouraging findings, these drugs have also been evaluated in a pre-chemotherapy setting. In addition, several novel drugs targeting non-AR signaling, including the novel taxoid compound cabazitaxel, antisense oligonucleotide OGX-011 (custirsen), sipuleucel-T immunotherapy and Alpharadin-based radiotherapy, have also been demonstrated to improve overall survival in CRPC. However, there is no consensus with regard to the sequence in which these novel drugs and taxanes should be used in the treatment of CRPC. In this review, we summarize recently developed and developing novel agents for use against CRPC. We also discuss the sequence of use of these agents and taxanes, mainly from the standpoint of factors related to drug resistance.

AB - Until 2010 docetaxel was the only agent with a proven survival benefit in the treatment of castration-resistant prostate cancer (CRPC). Recent evidence suggests that CRPC is caused by augmented androgen/androgen receptor (AR) signaling involving AR hypersensitivity, promiscuous activation of the AR, de novo production of androgens and activation of the AR by cytokines and growth factors; these findings have led to the development of novel agents targeting AR signaling. Several novel drugs targeting the AR axis, including the cytochrome P17 inhibitor abiraterone acetate and anti-androgen enzalutamide (MDV3100), have shown promising results in prolonging survival in clinical trials in a postchemotherapy setting. Because of these encouraging findings, these drugs have also been evaluated in a pre-chemotherapy setting. In addition, several novel drugs targeting non-AR signaling, including the novel taxoid compound cabazitaxel, antisense oligonucleotide OGX-011 (custirsen), sipuleucel-T immunotherapy and Alpharadin-based radiotherapy, have also been demonstrated to improve overall survival in CRPC. However, there is no consensus with regard to the sequence in which these novel drugs and taxanes should be used in the treatment of CRPC. In this review, we summarize recently developed and developing novel agents for use against CRPC. We also discuss the sequence of use of these agents and taxanes, mainly from the standpoint of factors related to drug resistance.

UR - http://www.scopus.com/inward/record.url?scp=84878667224&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84878667224&partnerID=8YFLogxK

U2 - 10.2174/15680096113139990078

DO - 10.2174/15680096113139990078

M3 - Review article

C2 - 23517595

AN - SCOPUS:84878667224

VL - 13

SP - 444

EP - 459

JO - Current Cancer Drug Targets

JF - Current Cancer Drug Targets

SN - 1568-0096

IS - 4

ER -